What Causes Retinoblastoma? A Look at Genes and Risk Factors

Retinoblastoma is a malignant tumor of the retina, the light-sensitive layer at the back of a child’s eye, and it almost always traces back to changes in the RB1 gene on chromosome 13. Losing the brake that RB1 normally provides allows retinal cells to multiply unchecked, producing an intraocular malignancy that can spread beyond the eye if left untreated.

Because the retina grows rapidly in young children, these tumors can emerge within the first months or years of life, which is why most cases are caught before age five.

You’ll find here a clear walk-through of retinoblastoma causes and risk factors, plus how those causes shape early warning signs, family screening, and long-term outlook for affected children.

Retinoblastoma and the Role of the RB1 Gene

A retinal tumor starts when the genetic machinery that controls cell division fails. Every cell carries two copies of the RB1 tumor suppressor gene, one from each parent, and together they restrain runaway growth. When both copies are disabled in the same retinal cell, the restraints disappear and a tumor can form. Chromosome 13q14, the precise address of the RB1 gene, is where those critical changes happen.

The retina finishes most of its development before birth, but it keeps growing and maturing during the first years of life. Rapid cell division during that window gives a damaged RB1 gene more chances to slip past the body’s normal checks. That timing helps explain why retinoblastoma is overwhelmingly a disease of early childhood rather than later life.

Why RB1 matters so much

RB1 belongs to a class of genes that protect against cancer by slowing cell division and triggering damaged cells to self-destruct. In a healthy retina, RB1 proteins act like a careful editor, blocking copies from being made until the cell is ready. With RB1 disabled, retinal cells skip those checkpoints and stack up into a white-gray mass visible through the pupil.

This single gene accounts for roughly 95 percent of retinoblastoma cases, a figure cited by the National Cancer Institute, making it the central player in nearly every diagnosis.

Hereditary Versus Sporadic Forms of the Disease

Retinoblastoma comes in two basic forms, and the distinction shapes everything from age at diagnosis to lifetime cancer risk. About 40 percent of cases are hereditary, caused by a germline RB1 mutation carried in every cell of the body from birth. The remaining 60 percent are sporadic, driven by somatic mutations that arise on their own in a developing retinal cell.

The hereditary form tends to announce itself earlier because the first RB1 copy is already missing in every cell, leaving only one mutation standing between the child and a tumor. Sporadic cases require two independent accidents in the same retinal cell, a statistically rarer event that pushes the average age of diagnosis closer to two years. Both forms share the same biology, but the family implications differ sharply.

Second primary cancers after hereditary retinoblastoma

Children born with a germline RB1 mutation carry that vulnerability in every tissue, not just the retina. The American Academy of Ophthalmology notes that this group faces a higher lifetime risk of osteosarcoma, soft tissue sarcoma, and melanoma, often appearing decades after the original eye tumor is treated. Survivors benefit from long-term surveillance well into adulthood, a reality that distinguishes hereditary cases from sporadic ones in every clinical guideline.

That lifelong surveillance hints at why researchers spent decades asking how a single tumor could keep returning across generations.

Knudson’s Two-Hit Hypothesis and How Tumors Form

More than fifty years ago, statistician Alfred Knudson proposed that retinoblastoma develops only after both copies of the RB1 gene lose function in the same cell. The two-hit hypothesis, now confirmed at the molecular level, explains why some children develop tumors in both eyes while others develop just one.

In hereditary retinoblastoma, the first hit arrives at conception, present in every cell of the body. A second hit, a random mutation in a single retinal cell, is enough to trigger a tumor. Because that second event is likely to happen in at least one retinal cell over time, tumors often appear in both eyes and sometimes at several sites within the same eye.

In sporadic cases, both hits must occur independently inside a single retinal cell, an event so unlikely that the typical outcome is one tumor in one eye.

Why bilateral tumors point to germline mutations

Bilateral retinoblastoma is, in practical terms, a marker for the hereditary form. The Children’s Oncology Group treats bilateral disease as presumptive evidence of a germline RB1 mutation until genetic testing says otherwise. That presumption guides how aggressively siblings are screened and how carefully survivors are followed, since the germline mutation can be passed to the next generation.

Recognizable Patterns and Risk Factors in Children

Retinoblastoma is uncommon but not vanishingly rare. It affects roughly 1 in 15,000 to 20,000 live births worldwide, a range reported by the World Health Organization, with similar rates across most populations. Because the disease is rare, awareness of risk factors matters more than population-level statistics.

The strongest known risk factor is a family history of retinoblastoma, especially a parent or sibling known to carry an RB1 mutation. Children in such families can be screened from birth, often under anesthesia, to catch tumors at their smallest. Without a family history, diagnosis usually depends on a parent or pediatrician spotting an early sign, because most sporadic cases offer no warning before symptoms appear.

Patterns that suggest hereditary disease

Several clinical clues raise the probability of a germline RB1 mutation:

• ▸Bilateral tumors: Cancer in both eyes almost always indicates hereditary retinoblastoma.
• ▸Diagnosis before age one: Earlier onset correlates strongly with inherited mutations.
• ▸Multiple tumor foci: Several separate tumors within a single retina suggest a germline event.
• ▸Family history of eye cancer: A parent, sibling, or close relative with retinoblastoma is the clearest red flag.
• ▸Known parental RB1 mutation: Even unaffected carriers pass the mutation to roughly half of their children.

From Cause to Consequence: Why Early Signs Demand Attention

The genetic events that cause retinoblastoma leave fingerprints visible to a careful observer. Leukocoria, a white pupillary reflection that shows up in flash photographs, is the single most commonly reported warning sign. A healthy eye reflects red because of blood in the choroid, but a tumor blocks that glow with white tissue. Parents often describe the effect as a cat-like gleam in one or both eyes under low light.

Strabismus, a new drift or misalignment of the eyes, frequently accompanies or even precedes the leukocoria finding. Less common presentations include persistent red eye, swelling, complaints of pain, or vision loss noticed when an older child covers one eye and struggles with the other. Any of these signs in a young child should prompt an urgent exam by a pediatric ophthalmologist.

“Skip the wait-and-see approach. A white pupil in a flash photo or a sudden eye turn in a child under three is not a “probably nothing” situation. Prompt evaluation can mean the difference between saving the eye and losing it.

Untreated retinoblastoma can extend along the optic nerve into the brain, seed the lining of the brain and spinal cord, or spread through the bloodstream to bone marrow. Once the tumor escapes the eye, the condition becomes life-threatening, which is why the gap between first sign and first exam matters so much.

When those red flags appear, families usually need more than reassurance; laboratory confirmation becomes the next practical step.

Genetic Testing and What It Means for Families

Blood tests can identify germline RB1 mutations with high accuracy, and tumor tissue can be analyzed when blood results are unclear. Genetic testing clarifies whether the case is hereditary or sporadic, which directly shapes surveillance, treatment intensity, and counseling for relatives.

A confirmed hereditary diagnosis changes the family’s roadmap. Siblings of an affected child need ophthalmologic screening from birth through at least age five, often under anesthesia so the entire retina can be examined. Genetic counseling helps parents understand recurrence risks in future pregnancies, including the option of prenatal or preimplantation testing for the known familial mutation. The American Cancer Society recommends genetic counseling for any family in which a germline RB1 mutation has been identified.

What the test results actually tell you

A positive germline result confirms hereditary retinoblastoma and explains bilateral or early-onset disease. A negative blood test does not always rule out hereditary disease, because some mutations hide in parts of RB1 that standard tests miss or because the mutation is confined to retinal cells in a rare mosaic pattern. Tumor testing can sometimes catch those hidden cases by comparing the tumor’s DNA to the child’s blood DNA.

Mosaic cases expose how much current testing still misses, pushing researchers to refine the tools parents rely on.

Limits of Current Knowledge and the Road Ahead

A small minority of retinoblastoma tumors lack identifiable RB1 mutations, suggesting other molecular drivers. Research into MYCN amplification, a gene that can drive aggressive neuroblastoma, points to a rare, fast-growing retinoblastoma variant that does not depend on RB1 loss. These cases are uncommon but clinically important, because they often resist standard therapies and require specialized protocols at centers such as St. Jude Children’s Research Hospital.

Improved genetic screening promises earlier detection, more precise prognostication, and treatment tailored to each tumor’s molecular profile. Liquid biopsies, which look for tiny amounts of tumor DNA in blood or fluid from the eye, are being studied as a way to track treatment response without repeated anesthesia. Parents concerned about risk should consult a pediatric oncologist or genetic counselor rather than rely on general information, because family-specific variables shape every recommendation.

Bottom Line

Retinoblastoma is fundamentally a genetic disease, driven by the loss of both copies of the RB1 tumor suppressor gene in a developing retinal cell. Whether that loss is inherited or happens spontaneously shapes the age of onset, the pattern of tumors, and the lifetime cancer risk for the child and the family.

FAQ